Search results for " liver disease"

showing 10 items of 559 documents

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.

2011

Clinical outcomes of recurrent hepatitis C virus after liver transplantation are difficult to predict. We evaluated collagen proportionate area (CPA), a quantitative histological index, at 1 year with respect to the first episode of clinical decompensation. Patients with biopsies at 1 year after liver transplantation were evaluated by Ishak stage/grade, and biopsy samples stained with Sirius red for digital image analysis were evaluated for CPA. Cox regression was used to evaluate variables associated with first appearance of clinical decompensation. Receiver operating characteristic (ROC) curves were also used. A total of 135 patients with median follow-up of 76 months were evaluated. At 1…

AdultMaleTime FactorsAdolescentBiopsyHepatic Veins/physiopathologyKaplan-Meier EstimateLiver Cirrhosis/metabolism/pathology/physiopathology/*surgery/virologyRisk AssessmentSensitivity and Specificity*Image Interpretation Computer-AssistedYoung AdultPredictive Value of TestsRecurrenceRisk FactorsLondonHumansLiver/blood supply/*metabolism/pathology/*surgery/virologyChildAgedProportional Hazards ModelsRetrospective Studiesliver transplantationLiver Transplantation/*adverse effectsMiddle AgedROC CurveCollagen/*metabolismFemaleHepatitis C/complications/metabolism/pathology/physiopathology/*surgeryEnd Stage Liver Disease/pathology/physiopathology/*surgery/virologyVenous Pressure
researchProduct

Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis

2002

Abstract Background. Patients with chronic hepatitis C infected by hepatitis A virus have a substantial risk of fulminant hepatitis or death, while the course of hepatitis A virus is uncomplicated in most subjects with chronic hepatitis B. Aim. To evaluate the prevalence of anti-hepatitis A virus antibodies and the incidence of hepatitis A virus seroconversion in a nationwide sample of 530 patients with chronic hepatitis B and/or hepatitis C infection initially susceptible to this infection after a follow-up of some years. Results. The overall anti-hepatitis A virus prevalence was 85.7%, with no difference between males and females. By the age of 50 years, almost all patients were found to …

AdultMalemedicine.medical_specialtyAdolescentHepatitis C virusmedicine.disease_causeHepatitis A AntibodiesVirusHepatitis B ChronicSeroepidemiologic StudiesInternal medicinemedicineHumansSeroconversionFulminant hepatitisAgedHepatitis B virusHepatologybusiness.industryIncidenceGastroenterologyHepatitis CHepatitis BHepatitis AHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyChronic liver disease; Hepatitis A virus superinfection; Hepatitis B virus; Hepatitis C virus;ItalyHepatitis A AntibodieFemalebusinessViral hepatitisHepatitis A Virus HumanHuman
researchProduct

Clinical features of oral lichen planus. A retrospective study of 65 cases

2010

Objectives: To describe the clinical features of patients diagnosed with oral lichen planus (OLP) and to establish the prevalence of its malignant transformation in our setting. Study design: A retrospective study was made of 65 patients clinically and histologically diagnosed with OLP in the Service of Oral Surgery (Dental Clinic of the University of Barcelona, Spain) in the period 1990-2005. A descriptive and bivariate statistical analysis was made. Results: The mean patient age was 59 years (SD ± 14.9). Most of the patients (61%) were women, and the most frequent location of the lesions was the buccal mucosa (90.8%). White forms of OLP were noted in 66% of the cases, and 46.2% of the pat…

AdultMalemedicine.medical_specialtyAdolescentLichensAlcohol abuseMalalties de la bocaChronic liver diseaseBuccal mucosaYoung AdultHepatitis víricastomatognathic systemDiabetes mellitusStatistical significanceTabacTobaccomedicineHumansLíquensViral hepatitisGeneral DentistryAgedRetrospective StudiesAged 80 and overbusiness.industryRetrospective cohort studyMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologySurgerystomatognathic diseasesMouth diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASPopulation studySurgeryOral lichen planusFemalebusinessLichen Planus Oral
researchProduct

Hepatic focal nodular hyperplasia: contrast-enhanced ultrasound findings with emphasis on lesion size, depth and liver echogenicity

2010

To correlate contrast-enhanced ultrasound (CEUS) findings of hepatic focal nodular hyperplasia (FNH) with lesion size, depth and liver echogenicity and to compare CEUS with baseline US. Two radiologists evaluated baseline US and CEUS examinations of 92 FNHs (mean size: 3.1 +/- 1.7 cm) in 71 patients (59 women and 12 men) to detect the "spoke-wheel" sign, central scar and feeding vessel. The FNHs were grouped and analysed by dimension, depth and liver echogenicity. At least one sign could be detected at CEUS in 27 out of 36 (75%) FNHs larger than 3 cm and in 17 out of 56 (30%) FNH measuring 3 cm or less (p 0.05) as well as between CEUS or baseline US/CD with regard to lesion size, depth or l…

AdultMalemedicine.medical_specialtyAdolescentStatistics as TopicSulfur HexafluorideContrast MediaSensitivity and SpecificityMicrobubbleLesionYoung AdultFocal nodular hyperplasia Ultrasonography Contrast media Microbubbles Liver diseasesmedicineHumansRadiology Nuclear Medicine and imagingLiver diseasesPhospholipidsAgedUltrasonographyNeuroradiologyObserver Variationmedicine.diagnostic_testbusiness.industryUltrasoundFocal nodular hyperplasiaReproducibility of ResultsEchogenicityInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseaseFocal Nodular HyperplasiaMicrobubblesFemaleRadiologymedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessContrast-enhanced ultrasoundEuropean Radiology
researchProduct

Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.

2016

Background & Aims GALAD and BALAD-2 are statistical models for estimating the likelihood of the presence of hepatocellular carcinoma (HCC) in individual patients with chronic liver disease and the survival of patients with HCC, respectively. Both models use objective measures, particularly the serum markers α-fetoprotein (AFP), AFP-L3, and des-γ-carboxyprothrombin. We aimed to validate these models in an international cohort of patients with HCC and assess their clinical performance. Methods We collected data on cancer diagnosis and outcomes of 6834 patients (2430 with HCC and 4404 with chronic liver disease) recruited from Germany, Japan, and Hong Kong. We also collected data from 229 pati…

AdultMalemedicine.medical_specialtyAsiaCarcinoma HepatocellularMedizinChronic liver diseaseGastroenterologyDecision Support TechniquesCohort Studies03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansneoplasmsSurvival analysisAgedHepatologybusiness.industryDiagnostic Tests RoutineLiver NeoplasmsGastroenterologyCancerMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesEurope030220 oncology & carcinogenesisHepatocellular carcinomaCohortAdenocarcinoma030211 gastroenterology & hepatologyFemalebusinessLiver cancerBiomarkersCohort studyClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.

2017

Background & Aims Controlled attenuation parameter (CAP) can be performed together with liver stiffness measurement (LSM) by transient elastography (TE) and is often used to diagnose fatty liver. We aimed to define the validity criteria of CAP. Methods CAP was measured by the M probe prior to liver biopsy in 754 consecutive patients with different liver diseases at three centers in Europe and Hong Kong (derivation cohort, n = 340; validation cohort, n = 414; 101 chronic hepatitis B, 154 chronic hepatitis C, 349 non-alcoholic fatty liver disease, 37 autoimmune hepatitis, 49 cholestatic liver disease, 64 others; 277 F3-4; age 52 ± 14; body mass index 27.2 ± 5.3 kg/m2). The primary outco…

AdultMalemedicine.medical_specialtyBiopsyAutoimmune hepatitisHepatic steatosiDiagnostic accuracyGastroenterology03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineNonalcoholic fatty liver diseaseMedicineHumansLiver stiffness measurementAgedFibroScanHepatologymedicine.diagnostic_testbusiness.industryFatty liverReproducibility of ResultsLiver biopsyHepatologyMiddle Agedmedicine.diseaseFatty LiverCross-Sectional StudiesLiverROC Curve030220 oncology & carcinogenesisLiver biopsyElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleSteatosisTransient elastographybusinessNon-alcoholic fatty liver diseaseJournal of hepatology
researchProduct

Impact of Italian Score for Organ Allocation System on Deceased Donor Liver Transplantation: A Monocentric Competing Risk Time-to-Event Analysis

2019

Background: Liver transplantation (LT) is the only definitive and curative treatment for patients with end-stage liver disease and hepatocellular carcinoma. We aimed to evaluate the impact of the Italian score for organ allocation (ISO) in terms of the waiting-list mortality, probability of LT, and patient survival after LT. Patient and methods: All of the adult patients on the waiting list for LT at our institute from January 2014 to December 2017 were included in the study. The probabilities of death while on the waiting list, dropout from the list, and LT were compared by means of cumulative incidence functions, in a competing risk time-to-event analysis setting. Uni- and multivariable l…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsWaiting Listsmedicine.medical_treatmentLiver transplantationCompeting risksLogistic regressionSeverity of Illness IndexGroup BEnd Stage Liver DiseaseLiver diseaseRisk FactorsInternal medicinemedicineHumansCumulative incidenceSurvival analysisRetrospective StudiesTransplantationbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseLiver TransplantationItalyHepatocellular carcinomaSurgeryFemalebusiness
researchProduct

Suspicious liver nodule in chronic liver disease: Usefulness of a second biopsy

2018

International audience; Purpose: To assess the usefulness of a second biopsy when the first one was inconclusive in patients with a liver nodule found during the follow-up for chronic liver disease.Materials and methods: Among 381 patients (544 nodules) included in a prospective study designed to evaluate the accuracy of imaging for the diagnosis of small hepatocellular carcinoma (HCC) in chronic liver disease, 254 nodules were biopsied. The following histological results were considered as conclusive: HCC, dysplastic or regenerative nodule, and other identified tumors (benign or malignant). For nodules with inconclusive results (e.g. fibrosis or no definite focal lesion), a second biopsy w…

AdultMalemedicine.medical_specialtyCarcinoma Hepatocellular[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingBiopsyChronic liver disease030218 nuclear medicine & medical imagingLesion03 medical and health sciences0302 clinical medicineFibrosisBiopsyHumansMedicineRadiology Nuclear Medicine and imagingIn patientProspective StudiesProspective cohort studyAgedAged 80 and overRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryLiver DiseasesLiver NeoplasmsNodule (medicine)General MedicineMiddle Agedmedicine.disease3. Good healthHepatocellular carcinomaChronic DiseaseFemale030211 gastroenterology & hepatologyRadiologymedicine.symptombusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals

2018

Background & Aims: Transient elastography (TE) is a noninvasive technique used to measure liver stiffness to estimate the severity of fibrosis. The range of liver stiffness measurements (LSMs) in healthy individuals is unclear. We performed a systematic review to determine the range of LSMs, examined by TE, in healthy individuals and individuals who are susceptible to fibrosis. Methods: We collected data from 16,082 individuals, in 26 cohorts, identified from systematic searches of Embase, Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for studies of liver stiffness measurements. Studies analyzed included apparently healthy adul…

AdultMalemedicine.medical_specialtyCirrhosisAdolescent03 medical and health sciencesYoung AdultBMI0302 clinical medicineInternal medicineDiabetes mellitusNonalcoholic fatty liver diseasemedicineHumansObesityAgedAged 80 and overCirrhosiAnthropometryHepatologybusiness.industryGastroenterologyBMI; Cirrhosis; Fibroscan; Obesity; Hepatology; GastroenterologyMiddle Agedmedicine.diseaseElasticityHealthy VolunteersFibroscanLiver030220 oncology & carcinogenesisCohortElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleMetabolic syndromeTransient elastographybusinessBody mass indexDyslipidemiaClinical Gastroenterology and Hepatology
researchProduct

Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study*.

2005

Summary.  We carried out a multicentre study on 2830 patients with chronic liver disease from 79 liver units (25 in northern, 24 in central and 30 in southern Italy) to evaluate naturally acquired immunity against hepatitis A virus (HAV) in relation to age, sex, geographical area of origin and entity of liver disease, and to define the strategy for specific vaccination. Antibody to HAV (anti-HAV) was detected in 1514 (53.5%) of the 2830 patients tested; the prevalence was 50.4% in males and 59.1% in females. Both in central and southern Italy the prevalence of anti-HAV positive subjects increased with increasing age from 43.3 and 44.7%, respectively, in the 0–30-year-old subjects to 80.1 an…

AdultMalemedicine.medical_specialtyCirrhosisAdolescentHepatitis A AntibodiesChronic liver diseaseLiver diseaseSeroepidemiologic StudiesVirologyInternal medicinePrevalencemedicineHumansIn patientChildChronic liver disease HAV infection HAV vaccination HBV chronic infection HCV chronic infection Total anti-HAVAgedAged 80 and overHigh prevalenceHepatologybiologybusiness.industryLiver DiseasesInfantHepatitis AHepatitis AMiddle Agedmedicine.diseaseVaccinationCross-Sectional StudiesInfectious DiseasesItalyChild PreschoolImmunoglobulin GChronic DiseaseImmunologybiology.proteinFemaleAntibodybusinessHepatitis A Virus Human
researchProduct